Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The document serves as an amended notification regarding transactions of Directors and Persons Discharging Managerial Responsibility (PDMRs) under the US Retirement Savings Plan. It replaces an original announcement from May 11, 2012, to correct an administrative error concerning the notional allocation of American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure regarding internal share plan adjustments and contains no financial performance data.
Material Changes
The material change disclosed is a correction to a previous announcement. Due to an administrative error, the notional allocation of ADSs for one individual was incorrectly stated in the May 11, 2012 release. This filing corrects that specific figure while confirming all other details remain unchanged.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The only unusual item noted is the administrative error in the US Retirement Savings Plan revaluation notification.
Important Facts for Investors
- The filing corrects an error in the reported notional ADS allocation for Mr. E J Gray (indicated with an asterisk in the original text).
- The correction relates to a revaluation of the cash element of the notional investment held within the US Retirement Savings Plan on May 10, 2012.
- The transaction price for the ADSs was $45.50 per ADS.
- Specific notional ADS increases were reported for Dr. M M Slaoui (11), Dr. K Slaoui (9), Mr. W C Louv (16), Dr. D Pulman (29), Mr. E J Gray (22*), and Mrs. D P Connelly (1).